Abstract
6529 Background: The introduction of immunotherapy (IO) in the treatment of patients with cancer has significantly improved clinical outcomes. Herein we report on IO uptake in Ontario, Canada, a publicly funded healthcare system. Methods: We conducted a retrospective cohort study using provincial health administrative data to: 1) assess IO uptake in adult patients with advanced melanoma, bladder, lung, head and neck (HN) and kidney cancers; and 2) identify predictors of IO usage between 2011 (pre-IO funding) and 2019. The datasets were linked using unique encoded identifiers and analyzed at ICES. IO uptake was captured between cancer diagnosis and last follow up and reported as a proportion of the entire cohort and by tumor site and drug type. A competing risk Fine and Gray regression model with death as competing risk was used to identify factors associated with IO use. Results: Among 59,510 patients with one of the five advanced cancers of interest, 7,660 (12.9%) received IO. Details of IO uptake are summarized in Table. IO uptake increased yearly from 2011 (2.7%) to 2019 (34.0%). Uptake was highest in melanoma (48.2%) and lowest in HN cancer (5.8%). The most commonly used drugs used were pembrolizumab (41.1%) and nivolumab (40.5%). In adjusted analysis, predictors of lower IO uptake included older age (hazard ratio (HR) 0.953, 95%CI 0.934-0.972 with every additional 10 years), female sex (HR 0.859, 95%CI 0.819-0.9), lower income quintile (HR 0.893, 95%CI 0.83-0.96), history of hospital admission (HR 0.768, 95%CI 0.734-0.805), female oncologist (HR 0.942, 95%CI 0.892-0.995), and de novo stage 4 cancer (HR 0.918, 95%CI 0.873-0.966). Predictors of higher IO uptake were low Charlson score (HR 1.118, 95%CI 1.01-1.236) and previous radiation therapy (HR 1.438, 95%CI 1.367-1.512). IO uptake was heterogeneous across cancer centres levels (1 to 4) and regions. Conclusions: While the use of IO for advanced cancer has steadily increased over time, uptake is associated with patient and physician characteristics, as well as system level factors. This variation suggests potential inequity in access to these potentially life-prolonging drugs and should be further investigated and addressed.[Table: see text]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have